BlackRock, Inc. (BLK) 13D/13G Filings for Neoleukin Therapeutics, Inc. (NLTX)

BlackRock, Inc. 13D and 13G filings for Neoleukin Therapeutics, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime		 Transaction
Date		 Type Company
Symbol		 Filed By
Symbol		 Shares Owned
% Owned		 Shares Vs. Prev Report View
2022-07-08
4:57 pm
Sale		 2022-06-30 13G Neoleukin Therapeutics, Inc.
NLTX		 BlackRock Inc.
BLK		 45,542
2.100%		 -84,691decrease
(-65.03%)		 Filing
2022-02-02
7:18 pm
Sale		 2021-12-31 13G Neoleukin Therapeutics, Inc.
NLTX		 BlackRock Inc.
BLK		 130,232
6.100%		 -4,013decrease
(-2.99%)		 Filing
2021-02-02
3:13 pm
Purchase		 2020-12-31 13G Neoleukin Therapeutics, Inc.
NLTX		 BlackRock Inc.
BLK		 134,246
6.400%		 134,246increase
(New Position)		 Filing